Neuroprotective mechanisms of EGb-761

EGb-761 的神经保护机制

基本信息

  • 批准号:
    6821765
  • 负责人:
  • 金额:
    $ 20.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-09-15 至 2006-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ginkgo biloba extract (EGb 761 ; EGb) is a standardized extract and one of the most renowned natural compounds specifically to treat neurological conditions. The constituents from the extract are likely to have synergistic effects that have been shown to be protective against oxidative stress injury. However, the cellular mechanisms of protection afforded by Ginkgo biloba are still unclear. We tested the hypothesis that the neuroprotective action of EGb could be due partially to an induction of heme oxygenase 1 (HO1). We and others have reported that modulation of HO activity may well have direct physiological implications in stroke and in Alzheimer disease. Through the use of cultured neurons, we demonstrated that EGb induces HO1 in a dose-dependent manner. Interestingly, our preliminary results indicate that pre-treatment of primary neurons with EGb followed by washing out the cells and then inducing toxicity, either by H202 or glutamate, EGb revealed neuroprotection. This effect is abolished with the heme oxygenase inhibitor (SnPPIX). We are proposing that several of the protective effects of EGb in ischemic conditions could be mediated through beneficial actions of heme degradation and its metabolites. We will first determine the cerebral blood flow, the infarct size, and the neuronal death following cardiac arrest in EGb-treated WT mice and test whether these effects are significantly decreased in the HOI-/- mice. Then, we will determine whether EGb-induced changes in HO1 expression result in changes in iron homeostasis and cell survival in neuronal cultures derived from WT and HOI-/- mice. To further address possible cellular mechanisms of action, primary cultured neurons derived from WT and HOI-/- mice will be used to test their susceptibility to heme toxicity and their role in controlling the iron efflux. These results should indicate if EGb pretreatment can be protective against iron toxicity and cell death and if this protection is abolished in HOI-/- cells. Together, we will test this new hypothesis that some of the beneficial effects attributed to EGb could be attributed to HO1 induction itself and its biological actions. It could provide new pathways to support the theory that EGb could provide brain's resistance in conditions of ischemia and aged-related dementia.
描述(由申请人提供):银杏叶提取物(EGb 761; EGb)是一种标准化提取物,是最著名的天然化合物之一,专门用于治疗神经系统疾病。来自提取物的成分可能具有协同效应,已被证明对氧化应激损伤具有保护作用。然而,银杏叶提供的细胞保护机制仍不清楚。我们测试的假设,银杏叶提取物的神经保护作用可能部分是由于血红素加氧酶1(HO1)的诱导。我们和其他人已经报道了HO活性的调节可能在中风和阿尔茨海默病中具有直接的生理意义。通过使用培养的神经元,我们证明,EGb诱导HO 1的剂量依赖性的方式。有趣的是,我们的初步结果表明,用EGb预处理原代神经元,然后冲洗细胞,然后通过H2O2或谷氨酸诱导毒性,EGb显示了神经保护作用。血红素加氧酶抑制剂(SnPPIX)可消除这种作用。我们认为银杏叶提取物在缺血性疾病中的保护作用可能是通过血红素降解及其代谢产物的有益作用来介导的。我们将首先确定EGb处理的WT小鼠心脏骤停后的脑血流量、梗死面积和神经元死亡,并测试这些效应在HOI-/-小鼠中是否显著降低。然后,我们将确定EGb诱导的HO1表达变化是否会导致WT和HOI-/-小鼠神经元培养物中铁稳态和细胞存活的变化。为了进一步阐明可能的细胞作用机制,将使用WT和HOI-/-小鼠的原代培养神经元检测其对血红素毒性的易感性及其在控制铁流出中的作用。这些结果应该表明,如果EGb预处理可以保护铁毒性和细胞死亡,如果这种保护被取消在HOI-/-细胞。总之,我们将测试这一新的假设,一些有益的影响归因于银杏叶提取物可以归因于HO1诱导本身及其生物学作用。这可能为银杏叶提取物在缺血和老年性痴呆中提供脑抵抗力的理论提供新的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sylvain DORE其他文献

Sylvain DORE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sylvain DORE', 18)}}的其他基金

Testing brain penetrant iron chelators and investigating putative clearance pathway in ICH
测试脑渗透铁螯合剂并研究 ICH 中假定的清除途径
  • 批准号:
    10201369
  • 财政年份:
    2020
  • 资助金额:
    $ 20.44万
  • 项目类别:
Potential stroke therapeutic efficacy of FumET-CORM through the Nrf2 pathway
FumET-CORM 通过 Nrf2 通路的潜在中风治疗功效
  • 批准号:
    9751526
  • 财政年份:
    2019
  • 资助金额:
    $ 20.44万
  • 项目类别:
Regulation and Implication of Hemoglobin Clearance in Subarachnoid Hemorrhagic Patients
蛛网膜下腔出血患者血红蛋白清除率的调节及意义
  • 批准号:
    9332485
  • 财政年份:
    2016
  • 资助金额:
    $ 20.44万
  • 项目类别:
Regulation and Implication of Hemoglobin Clearance in Subarachnoid Hemorrhagic Patients
蛛网膜下腔出血患者血红蛋白清除率的调节及意义
  • 批准号:
    9182501
  • 财政年份:
    2016
  • 资助金额:
    $ 20.44万
  • 项目类别:
Better Understanding of the Neuroprotective Mechanisms of Korean Ginseng in Strok
更好地了解高丽参对中风的神经保护机制
  • 批准号:
    9128625
  • 财政年份:
    2012
  • 资助金额:
    $ 20.44万
  • 项目类别:
Better Understanding of the Neuroprotective Mechanisms of Korean Ginseng in Strok
更好地了解高丽参对中风的神经保护机制
  • 批准号:
    8708765
  • 财政年份:
    2012
  • 资助金额:
    $ 20.44万
  • 项目类别:
Better Understanding of the Neuroprotective Mechanisms of Korean Ginseng in Strok
更好地了解高丽参对中风的神经保护机制
  • 批准号:
    8369356
  • 财政年份:
    2012
  • 资助金额:
    $ 20.44万
  • 项目类别:
Better Understanding of the Neuroprotective Mechanisms of Korean Ginseng in Strok
更好地了解高丽参对中风的神经保护机制
  • 批准号:
    8543642
  • 财政年份:
    2012
  • 资助金额:
    $ 20.44万
  • 项目类别:
Stilbene's Contribution in Hemorrhagic Stroke
二苯乙烯在出血性中风中的作用
  • 批准号:
    8059681
  • 财政年份:
    2010
  • 资助金额:
    $ 20.44万
  • 项目类别:
Effect of Flavanol-Rich Cocoa Extract in Acute Neurodegenerative Conditions
富含黄烷醇的可可提取物对急性神经退行性疾病的作用
  • 批准号:
    8117138
  • 财政年份:
    2010
  • 资助金额:
    $ 20.44万
  • 项目类别:

相似海外基金

Neural Basis of Stress-Derailed Motherhood
压力脱轨母性的神经基础
  • 批准号:
    10666891
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Harnessing PET to Study the In Vivo Fate and Health Effects of Micro- and Nanoplastics
利用 PET 研究微塑料和纳米塑料的体内命运和健康影响
  • 批准号:
    10890903
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Altered microglia states and microglia-endothelial cell axis in relation to white matter disease progression in VCID
VCID 中小胶质细胞状态和小胶质细胞内皮细胞轴的改变与白质疾病进展相关
  • 批准号:
    10738860
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands
亚型选择性代谢型谷氨酸受体 PET 配体
  • 批准号:
    10576674
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Circadian Rhythms in Blood Brain Barrier Permeability and Increased Efficacy of Chemotherapy for Brain Metastases
血脑屏障通透性的昼夜节律和脑转移化疗疗效的提高
  • 批准号:
    10663717
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Glycogen synthase kinase 3 ligand discovery for Alzheimer’s disease
糖原合成酶激酶 3 配体发现治疗阿尔茨海默病
  • 批准号:
    10637434
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Assessing Diffusion MRI Metrics for Detecting Changes of Synaptic Density in Alzheimer's Disease
评估弥散 MRI 指标以检测阿尔茨海默病突触密度的变化
  • 批准号:
    10739911
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers
支持在吸烟者 2 期临床研究中评估 mGlu2 PAM SBP-9330 的安全性/毒理学、ADME 和 CMC 活动
  • 批准号:
    10829189
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Probing D2 and 5HT-2A mechanisms in early visual processing in V1
探索 V1 早期视觉处理中的 D2 和 5HT-2A 机制
  • 批准号:
    10605769
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Develop in vivo PET imaging probes for ROCK2 as a biomarker of early Alzheimer's disease.
开发 ROCK2 的体内 PET 成像探针作为早期阿尔茨海默病的生物标志物。
  • 批准号:
    489145
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了